Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — Henlius — H1 2021 Earnings Presentation
34 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, August 2021
Slide 1: Henlius 1H21 Results Investor Presentation
Henlius (2696.HK) 1H21 Results Investor Presentation August 2021
Slide 2: Disclaimer
Disclaimer Henlius, the representor or the provider does not make any warranties, statements or representations, express or implied, on the content of this document (the content of this document may also include forward-looking statements), including but not limited to statements about the timelines
Slide 3: Company Overview and Strategy
Company Overview and Strategy
Slide 4: Company Mission & Key Milestones
Company Mission & Key Milestones HLX10 (PD-1 mAb, serplulimab) NDA Accepted by Mission: 2021.04 NMPA and Proposed to be Granted Priority Review Affordable Innovation, Reliable Quality 2020.12 HLXO1 (rituximab) for Rheumatoid Arthritis indication NDA Accepted by NMPA 2020.12 HLX03 (adalimumab, ;Q34iz
Slide 5: Management Team: More Executives Joined Henlius with Global Background in Recent Years
Management Team: More Executives Joined Henlius with Global Background in Recent Years Joined Henlius in Mar 2019 25 years of commercial operation experience in pharmaceutical industry Former business head, business vice president and general manager at Bayer China, Roche China and Amgen China MBA i
Slide 6: Company Size: the Number of Employees Rapidly Grew with Commercial Team Expanding Quickly
Company Size: the Number of Employees Rapidly Grew with Commercial Team Expanding Quickly Number of Employees 72 Commercial Team ? ' 1,873 7 . 1629, : mY | 310 395 451 . 19.0% 21.1% 22.8% | of Total of Total of Total Employees Employees Employees . 1H20 2020 1H21 305 259 544 241 451 172 6 soso net,
Slide 7: Company Strategy: Maximize Biosimilar Commercial Value, Accelerate Diversified Innovation
Company Strategy: Maximize Biosimilar Commercial Value, Accelerate Diversified Innovation with Full Speed Strategic Goals Stage 1: Biosimilar Stage 2: Diversified Innovation While maximizing biosimilar Build comprehensive commercial capability | Accelerate transformation towards diversified commerci
Slide 8: 1H21 Review: Products and Pipeline
1H21 Review: Products and Pipeline @ Henlius
Slide 9: R&D: Total Expenditure Continued to Grow with More on Innovative Drugs
R&D: Total Expenditure Continued to Grow with More on Innovative Drugs R&D Investment (Unit: 100 million) R&D Expense / Total R&D Investment Innovative Drug R&D/Total R&D Increased 70% 61% 100% 85.0% 60% 54% 80% 60% 9.54 50% 43% TST 7.39 40% 40% 38% 20% 30% + 0% + 1H20 2H20 1H21 2018 2019 2020 1H21
Slide 10: Bio-Innovative: In-house Integrated R&D Platform
Innovative Bio-Innovative: In-house Integrated R&D platform Covering apie Innovative Targets [Ee Be a a a 7 Under NDA Ea is MSEHSolid Tumours 2+ T priority Review XKGbio Metastatic Esophageal Squamous-Cell Carcinoma 1L Squamous Non-Small CellLung Cancer 1L [SRREWNMIRSSIS INTE +Chemo PD-1 3 Extensive
Slide 11: Focus on Lung and GI Cancer: PD-1 as the Opportunity and Foundation
. Focus on Lung and GI Cancer: PD-1 as the Opportunity and Foundation Product Target Indication Pre-clinical IND Phi Phil Phill NDA Launched Squamous Non-Small Cell Lung Cancer 1L Global multi-centre clinical trial HLX10+Chemo PD-1 Neo-/adjuvant Treatment HLX10+Chemo —— PD-1 of Gastric Cancer - [ess
Slide 12: Focus on Core Therapeutic Areas: Lung Cancer
Focus on Core Therapeutic Areas: Lung Cancer PD-1+Bio-Innovative: Lung Cancer TA well covered 1st Line Treatment 24 Line + Treatment Potential Products HLX04 (bevacizumab, HLX208 (BRAF Inhibitor) Phase / HLX20 (PD-L1) Phase! VEGF) NDA HLX10+HLX04 (PD- 1+ VEGF) Phase Ij] HLX13 (ipilimu- — HLX12 (ramu
Slide 13: Focus on Core Therapeutic Areas: Lung Cancer
Focus on Core Therapeutic Areas: Lung Cancer Serplulimab (PD-1): Competitive Domestically & Internationally Product Target Indication Pre-Clinical IND Phi Phil Phill NDA — Launched HLX10+Chemo PD-1 Squamous Non-Small Cell Lung Cancer 1L _ [SS ctob2t mutei-centre clinical trial HLX10+Chemo PD-1 Exten
Slide 14: Focus on Core Therapeutic Areas: Gastrointestinal Cancer
Focus on Core Therapeutic Areas: Gastrointestinal Cancer Effective Combination of Innovative and Mature Products to Solve the Unmet Needs of Gastrointestinal Caner Neo-/adjuvant 1st Line Treatment 24 Line + Treatment HLX10+Chemo (PD-1+ iS Chemo) Phase II Ja0ue) D4seyH Others KRAS+ BRAF+ ia) o o 2 i)
Slide 15: Actively Promote HLX208 (BRAF V600E Inhibitor)
Actively Promote HLX208 (BRAF V600E Inhibitor) Clinical Trials and Accelerate the Launch Bio-Innovative Strategic Significance Key Clinical Trials Planned + “Fast-to-market” project + HLX208 is expected to be the second BRAF inhibitor in Lung + Non-Small Cell Lung Cancer Ph2 Cancer launched in China
Slide 16: Biosimilar: Blockbuster Drugs
Biosimilar: Blockbuster Drugs such as 3NFR°, NHHI®, NIA Global “_ comes: Fosunmiaeis @ BiosiDUS Product (Reference Target Indications Drug) TAR Non-Hodgkin Lymphoma and Chronic ey (rituximab) (1) eax) Lymphocytic Leukemia @armay Sf ar cipia | a mentee HER2 Breast Cancer and a ° a (trastuzumab)(2) Me
Slide 17: Biosimilar: Multiple Blockbuster Drugs Have Competitive Advantages in China
Biosimilar: Multiple Blockbuster Drugs Have Competitive Advantages in China SRF? (rituximab) SHH (trastuzumab) 17 Product positioning: become a leader in China’s rituximab market First-mover advantage - First biosimilar in China, first domestic rituximab, 20 months earlier than No.2 The first & the
Slide 18: Biosimilar: Global Footprint Covers EU/US Markets and More
Biosimilar: Global Footprint Covers EU/US Markets and More Farmade Colombia Accord Essex (1061.HK) + _ Exclusive licensing and commercial + Exclusive commercial rights of trastuzumab + Co-development and exclusive license rights of rituximab (HLX01) in (HLX02) in over 70 countries and regions in agr
Slide 19: Efficiently Promote IND Application of Pre-clinical Products
Efficiently Promote IND Application of Pre-clinical Products + Recognize the value of pre-clinical pipeline and accelerate the submission of IND applications for CD38, LAG-3, CD73 targets products domestically and globally. + IND application of two bispecific products is expected to be submitted in
Slide 20: 1H21 Review: Manufacturing
1H21 Review: Manufacturing @ Henlius
Slide 21: 80,000 80,000 80,000 80,000 20,000 20,000 • • : • : • • •
80,000 80,000 80,000 80,000 20,000 20,000 • • : • : • • • • • • ’ • • • •
Slide 22: Songjiang First Plant: Pilot Conventional and Continuous Flow Workshops Completed
Songjiang First Plant: the construction of pilot conventional workshop and continuous flow workshop have been completed The continuous flow workshop construction has been completed and the continuous flow pilot production plan has been initiated for the Songjiang First Plant. ; Continuous Flow , , ’
Slide 23: Songjiang Second Plant: Project Construction Progressing Smoothly
Songjiang Second Plant: the project construction is progressing smoothly Electromechanical 1 Substance and \ 1 : Pi Equipment Arrival} 1 Preparation Line Hl ‘Production 1 \_Verification , \ All Pile Foundation of Phase 1 Project Structure of Two Construction : ' Production q t Initiated Completed Bu
Slide 24: 1H21 Review: Commercial Operation
1H21 Review: Commercial Operation @ Henlius
Slide 25: 1H21 Sales: Sales Volume Continues to Increase
1H21 Sales: lead by ;MEH{K® and ;NFIR®, the sales volume continues to increase Composition of Income (Unit: RMB 100 million) 1H20 Ex-factory Volume (Unit: 1000 Vials) RAR me BIA goog 6.00 mI mSNEROL om UA = Other Income 5.00 4.00 3.00 2020 1H21 Note: internal data / Total Loss/Total Revenue Narrowed
Slide 26: Market Access Marketing Channel
• • • • • • • • Market Access Channel Marketing • • • • • • • • •
Slide 27: Trastuzumab: Accelerate Admission to Hospital, Continue to Increase Volume
jMHH{K® (trastuzumab) : Accelerate Admission to Hospital, Continue to Increase Volume Market Access Continues to Advance Obvious Price Advantage + Domestic market: completed bidding in all provinces and . municipalities in mainland China and inclusion into the + Reference drug Herceptin®: RMB 5,500/
Slide 28: Rituximab: Continue to Increase Volume and Have a Solid Market Position
INF R® (rituximab): Continue to Increase Volume and Have a Solid Market Position 28 Market Access Continues to Advance 30 provinces and municipalities had approved the inclusion of 100mg into the medical insurance procurement platform 28 provinces and municipalities had completed official platform/f
Slide 29: Adalimumab: Give Every Auto-immune Disease Patient Proper Treatment
3NjA32° (adalimumab) : Give Every Auto-immune Disease Patient Proper and Possible Treatment + Successfully included into the medical insurance procurement platform for 27 provinces and Municipalities + Jiangsu Wanbang will be responsible for the domestic ' commercial sales. Wanbang has a sizeable De
Slide 30: Serplulimab (PD-1) and Bevacizumab: Commercial Strategy
Serplulimab (PD-1) and Bevacizumab: Commercial Strategy Serplulimab (PD-1) - Cornerstone of I/O Combo: all tumor targeting, differentiated competition, ecosystem empowerment, globalization Differentiated development, Advance Combo Launch with excellence Globalization therapy, expand therapeutic area
Slide 31: @ Henlius
@ Henlius
Slide 32: Outlook for the second half of 2021
Outlook for the second half of 2021 Capitalize on first-entrant advantages and increase the global market coverage of products, continue to commercialize more products + HLX02;R#8t#*: consolidate the construction of the diagnosis and treatment ecosystem for HER2-positive patients. The sales team is
Slide 33: Performance Guidance for 2021
Performance Guidance for 2021
Slide 34: Henlius
@ Henlius 22NF Reliable Quality | Affordable Innovation